![CRLX101 / Nanoparticle / Docetaxel / Organic chemistry / Nanotechnology / Nanomaterials / Chemistry CRLX101 / Nanoparticle / Docetaxel / Organic chemistry / Nanotechnology / Nanomaterials / Chemistry](https://www.pdfsearch.io/img/e56f6eb1f2c03b6f990e8fcf5c382a25.jpg)
| Document Date: 2013-06-24 09:06:43 Open Document File Size: 49,82 KBShare Result on Facebook
City Maastricht / Cambridge / Petah Tikva / Pasadena / / Company Mersana Therapeutics Inc. / Cerulean Pharma Inc. / Netherlands Mersana Therapeutics Inc. / Bind Therapeutics Inc. / Calando Pharmaceuticals Inc. / Innovatiefonds Limburg / Teva Pharmaceutical Industries Ltd. / Arrowhead Research Corp. / Nedermaas Ventures / Thuja Capital / BioGeneration Ventures / COMPANIES AND INSTITUTIONS MENTIONED Arrowhead Research Corp. / / Country Israel / / Currency USD / / Event FDA Phase / Business Partnership / / Facility Aachen University / Utrecht University / Cancer Institute Corporate / / IndustryTerm platform technology / manufacturing process / / MedicalCondition cancers / Cancer / castration-resistant prostate cancer / CriPec polymeric nanoparticles Disease / advanced solid tumors / neovasculature surrounding tumors / premature dissociation / non-small cell lung cancer / / Organization Joost Holthuis University / Aachen University / Utrecht University / / Person Cristianne Rijcken / Kai-Jye Lou / Cristal Therapeutics / covering CriPec platform technology Cristal / / Position CEO / Writer / cofounder and CEO / / Product CRLX101 / HIF1A / FOLH1 / CriPec / / ProvinceOrState California / Massachusetts / / Technology alpha / pharmacokinetics / linear CDP technology / CriPec platform technology / /
SocialTag |